ERBB2 and breast cancer: Other combinations are being evaluated in phase I-II trials, such as: T-DXd with pembrolizumab (NCT04042701) or durvalumab or durvalumab plus paclitaxel (NCT04538742), in metastatic HER2-positive BC; T-DXd with durvalumab plus paclitaxel in metastatic HER2-low BC (NCT04556773); Sacituzumab govitecan with pembrolizumab (NCT04468061) or with atezolizumab (NCT03424005).